p53, guardian of the genome
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p53, famously known as the ‘Guardian of the genome’ plays a key role in manifestation of cellular senescence via several different mechanisms (Lane, 1992; Kastenhuber and Lowe, 2017).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Lane, 1992
In the citing paper
“p53 is an crucial tumor suppressor that is mutated in more than 50% of human cancers”
From USP10 Regulates p53 Localization and Stability by Deubiquitinating p53 (2010) · cites this paper as Lane, 1992
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
Maltzman, W., & Czyzyk, L. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1689 · Cited by 893
Research works printed but not linked: 3
- Sturzbecher, H.-W. Oncogene (in the press).
- Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. Cancer Res. 51, 6304–6311 (1991).
- Bischoff, F. Z. et al. Cancer Res. 50, 7979–7984 (1990).
Cited by
Items 301–400 of 1,031
Histopathological Evaluation of Apoptosis in Cancer
Soini, Y., Pääkkö, P., & Lehto, V.-P. (1998) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65649-0 · Cited by 244
Lin, Z., & Fang, D. (2013) · Genes & Cancer · doi:10.1177/1947601912475079 · Cited by 237
Control of the cell cycle and apoptosis
Lundberg, A. S., & Weinberg, R. A. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00292-0 · Cited by 216
Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability
Nikolova, P. V., Henckel, J., Lane, D. P., & Fersht, A. R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14675 · Cited by 240
Self-citationp53 domains: identification and characterization of two autonomous DNA-binding regions.
Wang, Y., Reed, M., Wang, P., Stenger, J. E., Mayr, G., Anderson, M. E., Schwedes, J. F., & Tegtmeyer, P. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2575 · Cited by 239
Pettitt, A. R., Sherrington, P. D., Stewart, G., Cawley, J. C., Taylor, A. M. R., & Stankovic, T. (2001) · Blood · doi:10.1182/blood.v98.3.814 · Cited by 236
DNA damage and the DNA-activated protein kinase
Anderson, C. W. (1993) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(93)90144-c · Cited by 235
Small molecule induced reactivation of mutant p53 in cancer cells
Liu, X., Wilcken, R., Joerger, A. C., Chuckowree, I. S., Amin, J., Spencer, J., & Fersht, A. R. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt305 · Cited by 234
Induction of Radioresistance by a Nitric Oxide-Mediated Bystander Effect
Matsumoto, H., Hayashi, S., Hatashita, M., Ohnishi, K., Shioura, H., Ohtsubo, T., Kitai, R., Ohnishi, T., & Kano, E. (2001) · Radiation Research · doi:10.1667/0033-7587(2001)155[0387:iorban]2.0.co;2 · Cited by 237
“Likewise, wildtype TP53 plays an important role in safeguarding the genomic integrity of mammalian cells in response to cellular injury (15, 16).”
Surf the Post-translational Modification Network of p53 Regulation
Gu, B., & Zhu, W.-G. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.4283 · Cited by 235
“Regulating a vast pool of external stimuli, p53 exerts irreplaceable anti-neoplastic functions at homeostasis and thus is considered to be 'the guardian of the genome‘ [5].”
BackgroundTranscription — guarding the genome by sensing DNA damage
Ljungman, M., & Lane, D. P. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1435 · Cited by 237
Self-citationMidgley, C. A., Owens, B., Briscoe, C. V., Thomas, D. B., Lane, D. P., & Hall, P. A. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.5.1843 · Cited by 235
Self-citationWills, K. N., Maneval, D. C., Menzel, P., Harris, M. P., Sutjipto, S., Vaillancourt, M.-T., Huang, W.-M., Johnson, D. E., Anderson, S. C., Wen, S. F., et al. (1994) · Human Gene Therapy · doi:10.1089/hum.1994.5.9-1079 · Cited by 233
“…most common genetic alteration in human cancers (Bartek etal., 1991; Holl stein et al., 1991) genic In its proposed role as a "guardian of genome" (Lane, 1992), the p53 gene product functions as transcriptional activator of other genes which inhibit cell cycle progression from G, to S phase in…”
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes
Toss, A., Tomasello, C., Razzaboni, E., Contu, G., Grandi, G., Cagnacci, A., Schilder, R. J., & Cortesi, L. (2015) · BioMed Research International · doi:10.1155/2015/341723 · Cited by 228
Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth
Fei, P., Wang, W., Kim, S.-H., Wang, S., Burns, T. F., Sax, J. K., Buzzai, M., Dicker, D. T., McKenna, W. G., Bernhard, E. J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.012 · Cited by 231
“genic U2OS osteosarcoma cells were converted into a tumorip53 is frequently mutated in human cancer and is consid- genic state following injection of nude mice with U2OS cells ered a “guardian of the genome” in preventing cancer (Chan et harboring stable Bnip3L knockdown. Our results suggest that al., 2000; Lane, 1992…”
BackgroundAoki, M., Nata, T., Morishita, R., Matsushita, H., Nakagami, H., Yamamoto, K., Yamazaki, K., Nakabayashi, M., Ogihara, T., & Kaneda, Y. (2001) · Hypertension · doi:10.1161/01.hyp.38.1.48 · Cited by 232
Jung, T.-H., Park, J. H., Jeon, W.-M., & Han, K.-S. (2015) · Nutrition Research and Practice · doi:10.4162/nrp.2015.9.4.343 · Cited by 230
Liu, M., Li, C., Pazgier, M., Li, C., Mao, Y., Lv, Y., Gu, B., Wei, G., Yuan, W., Zhan, C., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008930107 · Cited by 228
DNA damage and p53-mediated cell cycle arrest: A reevaluation
Pellegata, N. S., Antoniono, R. J., Redpath, J. L., & Stanbridge, E. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15209 · Cited by 232
The N-terminal Domain of p53 is Natively Unfolded
Dawson, R., Müller, L., Dehner, A., Klein, C., Kessler, H., & Buchner, J. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.08.008 · Cited by 229
Cell type-specific inhibition of p53-mediated apoptosis by mdm2.
Haupt, Y., Barak, Y., & Oren, M. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00504.x · Cited by 228
Deconstructing networks of p53-mediated tumor suppression in vivo
Kaiser, A. M., & Attardi, L. D. (2018) · Cell Death & Differentiation · doi:10.1038/cdd.2017.171 · Cited by 227
Campbell, C., Quinn, A. G., Ro, Y.-S., Angus, B., & Rees, J. L. (1993) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12475717 · Cited by 229
Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53
Yoon, K. W., Byun, S., Kwon, E., Hwang, S.-Y., Chu, K., Hiraki, M., Jo, S.-H., Weins, A., Hakroush, S., Cebulla, A., et al. (2015) · Science · doi:10.1126/science.1261669 · Cited by 224
Nagy, Z., Esiri, M. M., & Smith, A. D. (1997) · Acta Neuropathologica · doi:10.1007/s004010050617 · Cited by 227
Apoptosis and Its Role in Human Disease
Barr, P. J., & Tomei, L. D. (1994) · Bio/Technology · doi:10.1038/nbt0594-487 · Cited by 225
Chemoresistance and targeted therapies in ovarian and endometrial cancers
Brasseur, K., Gévry, N., & Asselin, E. (2017) · Oncotarget · doi:10.18632/oncotarget.14021 · Cited by 224
Refined solution structure of the oligomerization domain of the tumour suppressor p53
Clore, G. M., Ernst, J., Clubb, R., Omichinski, J. G., Kennedy, W. M. P., Sakaguchi, K., Appella, E., & Gronenborn, A. M. (1995) · Nature Structural & Molecular Biology · doi:10.1038/nsb0495-321 · Cited by 222
p53-catalyzed annealing of complementary single-stranded nucleic acids.
Oberosler, P., Hloch, P., Ramsperger, U., & Stahl, H. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05893.x · Cited by 224
p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines.
Brachman, D. G., Beckett, M., Graves, D., Haraf, D. J., Vokes, E. E., & Weichselbaum, R. R. (1993) · PubMed · Cited by 222
Ordered and deterministic cancer genome evolution after p53 loss
Baslan, T., Morris, J. P., Zhao, Z., Reyes, J., Ho, Y.-J., Tsanov, K. M., Bermeo, J., Tian, S., Zhang, S., Askan, G., et al. (2022) · Nature · doi:10.1038/s41586-022-05082-5 · Cited by 221
Bauer, J. J., Sesterhenn, I. A., Mostofi, F. K., McLeod, D. G., Srivastava, S., & Moul, J. W. (1996) · Journal of Urology · doi:10.1016/s0022-5347(01)65641-6 · Cited by 225
Mutant p53 in Cancer Progression and Targeted Therapies
Zhu, G., Pan, C., Bei, J.-X., Li, B., Liang, C., Xu, Y., & Fu, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.595187 · Cited by 218
Berg, R. J., van Kranen, H. J., Rebel, H. G., de Vries, A., van Vloten, W. A., Van Kreijl, C. F., van der Leun, J. C., & de Gruijl, F. R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.274 · Cited by 224
Di Bartolomeo, M., Bajetta, E., Buzzoni, R., Mariani, L., Carnaghi, C., Somma, L., Zilembo, N., Di Leo, A., & ITMO Association (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960115)77:2<402::aid-cncr25>3.0.co;2-4 · Cited by 296
Barnes, D. M., Dublin, E. A., Fisher, C. J., Levison, D. A., & Millis, R. R. (1993) · Human Pathology · doi:10.1016/0046-8177(93)90158-d · Cited by 221
Singh, P., & Lim, B. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01199-y · Cited by 209
Mechanisms and implications of the age‐associated decrease in DNA repair capacity
Goukassian, D., Gad, F., Yaar, M., Eller, M. S., Nehal, U. S., & Gilchrest, B. A. (2000) · The FASEB Journal · doi:10.1096/fasebj.14.10.1325 · Cited by 218
Changes in Regenerative Capacity through Lifespan
Yun, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161025392 · Cited by 216
Apoptosis and necrosis in toxicology: A continuum or distinct modes of cell death?
Raffray, M., & Gerald M., C. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00037-5 · Cited by 214
p53 and the pathogenesis of skin cancer
BENJAMIN, C., & ANANTHASWAMY, H. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2006.12.006 · Cited by 214
“Therefore, p53 aids in the DNA repair or the elimination of cells that have excessive DNA damage (Lane, 1992; Levine, 1997).”
Backgroundp63 in Epithelial Survival, Germ Cell Surveillance, and Neoplasia
Crum, C. P., & McKeon, F. D. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102117 · Cited by 215
The Functions and Unique Features of LncRNAs in Cancer Development and Tumorigenesis
Taniue, K., & Akimitsu, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020632 · Cited by 213
Cordone, I., Masi, S., Mauro, F. R., Soddu, S., Morsilli, O., Valentini, T., Vegna, M. L., Guglielmi, C., Mancini, F., Giuliacci, S., et al. (1998) · Blood · doi:10.1182/blood.v91.11.4342 · Cited by 215
Interaction of p53 with the Human Rad51 Protein
Buchhop, S., Gibson, M. K., Wang, X. W., Wagner, P., Sturzbecher, H.-W., & Harris, C. C. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.19.3868 · Cited by 215
Levy, R., Smith, S. D., Chandler, K., Sadovsky, Y., & Nelson, D. M. (2000) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2000.278.5.c982 · Cited by 211
Overexpression of p53 and prognosis in breast cancer
Friedrichs, K., Gluba, S., Eidtmann, H., & Jonat, W. (1993) · Cancer · doi:10.1002/1097-0142(19931215)72:12<3593::aid-cncr2820721208>3.0.co;2-t · Cited by 211
Abid-Essefi, S., Baudrimont, I., Hassen, W., Ouanes, Z., Mobio, T. A., Anane, R., Creppy, E. E., & Bacha, H. (2003) · Toxicology · doi:10.1016/s0300-483x(03)00329-9 · Cited by 206
The importance of p53 location: nuclear or cytoplasmic zip code?
O’Brate, A., & Giannakakou, P. (2003) · Drug Resistance Updates · doi:10.1016/j.drup.2003.10.004 · Cited by 208
“…of cancer research. p53, often referred to as the " guardian of the genome, " is a sequence-specific transcription factor activated by diverse stress signals (Lane, 1992). p53 activation regulates genes involved in many cellular functions, the most important being cell cycle arrest and apoptosis.”
BackgroundRavagnan, L., Marzo, I., Costantini, P., Susin, S. A., Zamzami, N., Petit, P. X., Hirsch, F., Goulbern, M., Poupon, M.-F., Miccoli, L., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1202625 · Cited by 210
“This is true for genotoxic events requiring activation of the p53 pathway (Lane, 1992; Polyak et al., 1997) or a series of chemotherapeutic agents involving signaling through the ceramide pathway (Herr et al., 1997; Kolesnick and Kronke, 1998; Testi, 1996), through changes in cellular redox…”
BackgroundLiu, V. F., & Weaver, D. T. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.12.7222 · Cited by 208
Halazonetis, T. D., & Kandil, A. N. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06199.x · Cited by 205
TP53: a key gene in human cancer
Guimaraes, D. P., & Hainaut, P. (2002) · Biochimie · doi:10.1016/s0300-9084(01)01356-6 · Cited by 203
Holzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00810 · Cited by 203
Budanov, A. V. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3530 · Cited by 200
Portess, D. I., Bauer, G., Hill, M. A., & O'Neill, P. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2985 · Cited by 203
Excessive genomic DNA copy number variation in the Li–Fraumeni cancer predisposition syndrome
Shlien, A., Tabori, U., Marshall, C. R., Pienkowska, M., Feuk, L., Novokmet, A., Nanda, S., Druker, H., Scherer, S. W., & Malkin, D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802970105 · Cited by 203
Cancer as a Metabolic Disorder
Gyamfi, J., Kim, J., & Choi, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031155 · Cited by 197
Chromothripsis: A New Mechanism for Rapid Karyotype Evolution
Leibowitz, M. L., Zhang, C.-Z., & Pellman, D. (2015) · Annual Review of Genetics · doi:10.1146/annurev-genet-120213-092228 · Cited by 205
Potten, C. S., Merritt, A., Hickman, J., Hall, P., & Faranda, A. (1994) · International Journal of Radiation Biology · doi:10.1080/09553009414550101 · Cited by 201
Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer
Fontanini, G., Vignati, S., Bigini, D., Mussi, A., Lucchi, M., Angeletti, C., Basolo, F., & Bevilacqua, G. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.193 · Cited by 200
Cervical Cancer: Prevention, Diagnosis, and Therapeutics
Janicek, M. F., & Averette, H. E. (2001) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.51.2.92 · Cited by 199
Apoptosis: A Basic Physiologic Process in Wound Healing
Rai, N. K., Tripathi, K., Sharma, D., & Shukla, V. K. (2005) · The International Journal of Lower Extremity Wounds · doi:10.1177/1534734605280018 · Cited by 199
Pritchard, D. M., Watson, A. J. M., Potten, C. S., Jackman, A. L., & Hickman, J. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1795 · Cited by 198
Du, M., Peng, H., Singh, N., Isaacson, P., & Pan, L. (1995) · Blood · doi:10.1182/blood.v86.12.4587.bloodjournal86124587 · Cited by 200
Takenaka, I., Morin, F., Seizinger, B. R., & Kley, N. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.10.5405 · Cited by 197
Vascular senescence in cardiovascular and metabolic diseases
Katsuumi, G., Shimizu, I., Yoshida, Y., & Minamino, T. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00018 · Cited by 196
Humphrey, J. S., Price, K., Gupta, E., Baxter, A., Bird, J., Sonnichsen, D., & Naglich, J. (2003) · Chemoradiation in Cancer Therapy · doi:10.1007/978-1-59259-325-5_21 · Cited by 193
Nees, M., Homann, N., Discher, H., Andl, T., Enders, C., Herold‐Mende, C. C., Schuhmann, A., & Bosch, F. X. (1993) · PubMed · Cited by 195
Wavelength specific patterns of p53 induction in human skin following exposure to UV radiation.
Campbell, C., Quinn, A., Angus, B., Farr, P. M., & Rees, J. L. (1993) · PubMed · Cited by 195
Boland, C. R., Sato, J., Appelman, H. D., Bresalier, R. S., & Feinberg, A. P. (1995) · Nature Medicine · doi:10.1038/nm0995-902 · Cited by 197
Uversky, V. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17111874 · Cited by 192
“Because of its ability to induce apoptosis, cell-cycle arrest, or DNA repair, p53 is widely considered to be a tumor suppressor that serves as a guardian of the genome [96].”
BackgroundJiang, X.-H., Wong, B. C.-Y., Lin, M. C.-M., Zhu, G.-H., Kung, H.-F., Jiang, S.-H., Yang, D., & Lam, S.-K. (2001) · Oncogene · doi:10.1038/sj.onc.1204981 · Cited by 193
“The tumor suppressor gene p53 mediates either cell cycle arrest or apoptosis in response to DNA damage, thus acting as a molecular `guardian of the genome' (Lane, 1992).”
BackgroundRegulation of Mdm2-Directed Degradation by the C Terminus of p53
Kubbutat, M. H. G., Ludwig, R. L., Ashcroft, M., & Vousden, K. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5690 · Cited by 193
“Either of these responses prevents the replication of cells with damaged DNA, and loss of this protective function is proposed to allow the outgrowth of cells harboring potentially oncogenic mutations (34).”
BackgroundCLINICAL IMPLICATIONS OF THE p53 GENE
Sidransky, M. D., & Hollstein, P. D. (1996) · Annual Review of Medicine · doi:10.1146/annurev.med.47.1.285 · Cited by 194
Webley, K., Bond, J. A., Jones, C. J., Blaydes, J. P., Craig, A., Hupp, T., & Wynford-Thomas, D. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.8.2803-2808.2000 · Cited by 192
“We and others have demonstrated that one key signal pathway mediating replicative senescence involves the phosphoprotein p53, more widely recognized for its role as a tumor suppressor, which is known to mediate growth arrest in response to a wide variety of cellular stress signals including DNA damage (31, 40).”
BackgroundRadiosensitivity in Ataxia-telangiectasia: Anomalies in Radiation-induced Cell Cycle Delay
Beamish, H., & Lavin, M. F. (1994) · International Journal of Radiation Biology · doi:10.1080/09553009414550211 · Cited by 191
The Isoforms of the p53 Protein
Khoury, M. P., & Bourdon, J.-C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a000927 · Cited by 191
“Hence, p53 has been dubbed “the guardian of the genome” (Lane 1992).”
BackgroundVignola, A. M., Chanez, P., Chiappara, G., Siena, L., Merendino, A., Reina, C., Gagliardo, R., Profita, M., Bousquet, J., & Bonsignore, G. (1999) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(99)70225-3 · Cited by 192
Prognostic factors in early breast carcinoma
Mansour, E. G., Ravdin, P. M., & Dressier, L. (1994) · Cancer · doi:10.1002/cncr.2820741326 · Cited by 199
MEG3: an Oncogenic Long Non-coding RNA in Different Cancers
Al-Rugeebah, A., Alanazi, M., & Parine, N. R. (2019) · Pathology & Oncology Research · doi:10.1007/s12253-019-00614-3 · Cited by 190
Kim, S. P., Vale, N. R., Zacharakis, N., Krishna, S., Yu, Z., Gasmi, B., Gartner, J. J., Sindiri, S., Malekzadeh, P., Deniger, D. C., et al. (2022) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0040 · Cited by 187
Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities
Wang, W., Kandimalla, R., Huang, H., Zhu, L., Li, Y., Gao, F., Goel, A., & Wang, X. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.05.002 · Cited by 187
Activation of the cryptic DNA binding function of mutant forms of p53
Hupp, T. R., Meek, D. W., Midgley, C. A., & Lane, D. P. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.14.3167 · Cited by 189
Self-citationThe p53 gene and its role in human brain tumors
Bögler, O., Su Huang, H. ‐., Kleihues, P., & Cavenee, W. K. (1995) · Glia · doi:10.1002/glia.440150311 · Cited by 187
Cabelguenne, A., Blons, H., de Waziers, I., Carnot, F., Houllier, A.-M., Soussi, T., Brasnu, D., Beaune, P., Laccourreye, O., & Laurent-Puig, P. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1465 · Cited by 191
Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression
Girotti, M. R., Salatino, M., Dalotto-Moreno, T., & Rabinovich, G. A. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20182041 · Cited by 185
“The role of genome maintenance machinery is to detect and resolve DNA defects, ensuring low rates of spontaneous mutations during each cell generation (Lane, 1992).”
BackgroundJones, B. A., & Gores, G. J. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.6.g1174 · Cited by 186
“The p53 gene product acts as a genetic sentinel, acting to initiate the apoptotic process if excessive DNA damage occurs (79).”
BackgroundCarty, M. P., Zernik-Kobak, M., McGrath, S., & Dixon, K. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06487.x · Cited by 186
Genotoxicity of environmental tobacco smoke: a review
Husgafvel-Pursiainen, K. (2004) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2004.06.004 · Cited by 186
Foster, S. A., Demers, G. W., Etscheid, B. G., & Galloway, D. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.9.5698-5705.1994 · Cited by 160
Lessons learned from BRCA1 and BRCA2
Zheng, L., Li, S., Boyer, T. G., & Lee, W.-H. (2000) · Oncogene · doi:10.1038/sj.onc.1203968 · Cited by 188
“Consistent with the possibility that p53 may function as a caretaker, germline inactivation of p53 itself will lead to genome instability and an increased frequency in tumor formation (reviewed by Lane, 1992).”
BackgroundProkocimer, M., & Rotter, V (1994) · Blood · doi:10.1182/blood.v84.8.2391.2391 · Cited by 184
DNA damage-inducible gene p33ING2 negatively regulates cell proliferation through acetylation of p53
Nagashima, M., Shiseki, M., Miura, K., Hagiwara, K., Linke, S. P., Pedeux, R., Wang, X. W., Yokota, J., Riabowol, K., & Harris, C. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161151798 · Cited by 185
Intracellular Trafficking of Plasmids during Transfection Is Mediated by Microtubules
Vaughan, E. E., & Dean, D. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.004 · Cited by 183
Ryan, K. M., & Vousden, K. H. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3692 · Cited by 184
“p53 expression is elevated in response to stress, such as DNA damage or abnormal proliferative signals, and activation of p53 function is thought to prevent the outgrowth of cells which harbor potentially oncogenic alterations (23).”
BackgroundCrystal structure of human 53BP1 BRCT domains bound to p53 tumour suppressor
Derbyshire, D. J. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf383 · Cited by 185
A tiger behind many doors: multiple genetic pathways to malignant glioma
Louis, D. N., & Gusella, J. F. (1995) · Trends in Genetics · doi:10.1016/s0168-9525(00)89125-8 · Cited by 185
Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies
Xu-Monette, Z. Y., Medeiros, L. J., Li, Y., Orlowski, R. Z., Andreeff, M., Bueso-Ramos, C. E., Greiner, T. C., McDonnell, T. J., & Young, K. H. (2012) · Blood · doi:10.1182/blood-2011-11-366062 · Cited by 179
Metadata
- Authors
- Lane, D. P.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Lane, D. P.
- ORCID
- Lane, D. P.
- Venue
- Nature
- Published
- 1992-07
- Volume
- 358
- Issue
- 6381
- Pages
- 15-16
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2012053348
- Cited by
- 5,138
- References
- 19
- Citations by year
- 2026: 84 · 2025: 92 · 2024: 122 · 2023: 112 · 2022: 135 · 2021: 142 · 2020: 150 · 2019: 128 · 2018: 140 · 2017: 138 · 2016: 142 · 2015: 135 · 2014: 150 · 2013: 142 · 2012: 143
- FWCI
- 97.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- TP53, p53, TP53 mutation, cancer, genome stability, tumor suppressor
- MeSH terms
- Animals, Chromosome Mapping, DNA Damage, DNA Repair, DNA-Binding Proteins, Gene Expression Regulation, Humans, Oncogenes, Transcription Factors, Genes, Tumor Suppressor, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.